Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

By Yi-long Wu, Ying Cheng, Xiang-dong Zhou, K. Lee, K. Nakagawa, S. Niho, F. Tsuji, R. Linke, R. Rosell, J. Corral and 8 more. The Lancet Oncology, 2017

973 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/8b5122d48a01fa7384a6197076c5e6046f441c1b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Kerr
2. M. Hellmann

Citations in the corpus

• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “ARCHER 1050 is a randomised phase III study that compares dacomitinib with gefitinib in stage IV EGFR-mutated lung cancer patients without CNS metastasis [184, 185].”
• Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer (2018, background): “Patients who discontinued osimertinib 18 (38) Patient decision 1 (2) Adverse event 2 (4) Severe non-compliance to protocol 0 Condition under investigation worsened 13 (27)”